이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

부신암/종양(COMETE-CARE) 환자 관리를 위한 임상 루틴에서 분자 마커의 위치 (COMETE-CARE)

2026년 10월 1일 업데이트: Assistance Publique - Hôpitaux de Paris

The adrenal cancer research network "COMETE" is federating French research on rare adrenal cancers. COMETE achieved major breakthroughs in the molecular characterization of adrenocortical carcinomas (ACC) and malignant pheochromocytomas/paragangliomas (MPP). Recently, COMETE successfully derived potential biomarkers for prognosis, theranostic and follow-up. Those biomarkers have been retrospectively validated. However the benefit for patients in real life conditions is not yet established.

  • Main objective : to implement COMETE biomarkers as a routine standard of care for adrenal cancer.

  • The primary end point is double :

    • Proportion of biomarkers results provided within 3 months after surgery,
    • The proportion of "informative" biomarkers, corresponding to markers passing quality controls and returning a value that is not in the grey zone of the measure.
  • Secondary objective : to estimate the impact of COMETE biomarkers on patients management.

  • Secondary endpoints :

    • Proportion of patients with discrepant clinical and molecular markers ; for discrepancies, proportion of decisions impacted by biomarkers results
    • Proportion of high risk patients for whom an actionable molecular target was identified
    • Predictive value (positive and negative) of biomarkers to detect recurrences
    • Molecular signatures of "extraordinary responders" to treatments (corresponding to the exceptional RECIST complete response, or to the >80% tumor reduction sutained for >6months)
    • Correlation of molecular markers with morphological features (radiological and pathological) of the tumor

연구 개요

상세 설명

  • Adult patients with a malignant adrenal tumor before initial surgery are proposed to participate to the study.
  • Initial clinical management following current guidelines is applied, including clinical and morphological evaluation, hormone assays and adrenal surgery. A tumor sample from initial surgery , and a blood sample and a urine sample collected before surgery are included in the current research protocol. These samples are used to run prognostic molecular measurements, in order to classify patients as "low" or "high risk" of recurrence. For ACC samples, paraffin tumor samples will be sent to a centralized pathology facility, where 3' RNA sequencing will be performed on tumor RNA to classify tumors into previously established C1A/C1B prognostic classification. Circulating levels of miRNAs will be assayed from blood samples collected before surgery and used to classify tumors into prognostic categories as previously reported. Urine and plasma steroids profiles will be established using mass spectrometry to classify tumors into prognostic categories as previously reported. For MPP, molecular assays will include somatic genotyping, methylation assays and immunochemistry for the known recurrently altered genes, and used to classify tumors into prognostic categories as previously reported. These molecular results are returned by 3 months after surgery
  • Patients follow-up is then performed following current guidelines, with repeated visits (each ~3 months for ACC and ~6 months for MPP), including clinical, morphological evaluation, and hormone assays. A blood and a urine sample will also be collected for the current research protocol. These samples will be used to run molecular measurements aiming at identifying early recurrence. For ACC, circulating levels of miRNAs and urine and plasma steroids profiles will be measured every 3 months to classify tumors into prognostic categories as previously reported. For MPP, circulating levels of miRNAs will be measured every 6 months to classify tumors into prognostic categories as previously reported
  • For patients at high risk of recurrence, a molecular target will be searched by an extended genomic analysis of the tumor (exome sequencing and RNA sequencing), in search for molecular targets that may orient future treatments, if the disease recurs.

연구 유형

중재적

등록 (추정된)

450

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Paris, 프랑스, 75014
        • 모병
        • GH Paris Centre, Assistance Publique - Hôpitaux de Paris
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  • Patients 18 years of age and older
  • Patients with an adrenal tumor who will be operated or have been operated in the last 2 months of a potentially malignant adrenocortical (ACC) (any tumor with density > 10 UH) or pheochromocytoma or paraganglioma (MPP) (any stage, any secretion)
  • Patients affiliated with a social security regime
  • Patients who have signed an informed consent

Exclusion Criteria

  • Vulnerable populations : minors, pregnant or breastfeeding women, protected adults
  • Patients on AME (state medical aid)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Patients with ACC

These patients will be followed up and proposed a search for targetable molecular alterations

For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

For patients with ACC and patients with MPP : tumor sample during surgery

다른: Patients with MPP

These patients will be followed up and proposed a search for targetable molecular alterations

For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking

For patients with ACC and patients with MPP : tumor sample during surgery

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Baseline biomarkers results
기간: Within 3 months after surgery

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after initial surgery

Within 3 months after surgery

2차 결과 측정

결과 측정
측정값 설명
기간
M3 biomarkers results
기간: During follow-up (month 6)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M6 follow-up visit

During follow-up (month 6)
M6 biomarkers results
기간: During follow-up (month 9)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M9 follow-up visit

During follow-up (month 9)
M9 biomarkers results
기간: During follow-up (month 12)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M12 follow-up visit

During follow-up (month 12)
M12 biomarkers results
기간: During follow-up (month 15)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M15 follow-up visit

During follow-up (month 15)
M15 biomarkers results
기간: During follow-up (month 18)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M18 follow-up visit

During follow-up (month 18)
M18 biomarkers results
기간: During follow-up (month 21)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M21 follow-up visit

During follow-up (month 21)
M21 biomarkers results
기간: During follow-up (month 24)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M24 follow-up visit

During follow-up (month 24)
M24 biomarkers results
기간: During follow-up (month 27)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M27 follow-up visit

During follow-up (month 27)
M27 biomarkers results
기간: During follow-up (month 30)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M30 follow-up visit

During follow-up (month 30)
M30 biomarkers results
기간: During follow-up (month 33)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M33 follow-up visit

During follow-up (month 33)
M33 biomarkers results
기간: During follow-up (month 36)

Proportion of biomarkers and of informative biomarkers returned to physicians within 3 months after M36 follow-up visit

During follow-up (month 36)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Anne JOUINOT, Dr, APHP

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 10월 1일

기본 완료 (추정된)

2029년 12월 1일

연구 완료 (추정된)

2030년 6월 1일

연구 등록 날짜

최초 제출

2022년 12월 26일

QC 기준을 충족하는 최초 제출

2023년 2월 22일

처음 게시됨 (실제)

2023년 3월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • APHP210350
  • 2022-A00663-40 (기타 식별자: ID-RCB Number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다